This is a preview of subscription content, log in via an institution to check access.
Notes
The study was sponsored by Bayer Healthcare Co Ltd.
Reference
Dai Y, et al. Cost-effectiveness Analysis of Dienogest Compared With Gonadotropin-Releasing Hormone Agonist After Conservative Surgery for Endometriosis in China. Clinical Therapeutics : 9 Aug 2021. Available from: URL: http://doi.org/10.1016/j.clinthera.2021.07.002
Rights and permissions
About this article
Cite this article
Dienogest for endometriosis after surgery: better outcomes, lower cost. PharmacoEcon Outcomes News 886, 10 (2021). https://doi.org/10.1007/s40274-021-07988-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-07988-7